ArticleTranslational oncology2026
A single-nucleus transcriptomic characterization of EGFR G719X/S768I double-mutant lung adenocarcinoma identifies an immunosuppressive niche defined by COL4A3-CD44 interaction.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
EGFR double mutations (G719X/S768I) represent a clinically recalcitrant subtype of lung adenocarcinoma (LUAD) characterized by diminished tyrosine kinase inhibitor (TKI) sensitivity. However, the specific tumor microenvironment (TME) features and intercelluar crosstalk driving this therapeutic resistance poorly defined. We performed single-nucleus RNA sequencing (snRNA-seq) on formalin-fixed paraffin-embedded (FFPE) tissues from six EGFR G719X/S768I double-mutant (EGFR_double) and five no EGFR mutation (Non_EGFR) LUAD patients. To provide a comprehensive reference, we integrated our FFPE data with publicly fresh-tissue single cell RNA sequencing (scRNA-seq) data with seven EGFR single-mutant LUAD (EGFR_single) and five adjacent normal (Adjacent), generated a comprehensive atlas of 246,086 cells. Findings were further validated using multiplex immunohistochemistry (mIHC) and pharmacogenomic profiling. We identified a specialized EMT-like malignant subpopulation (MP4) uniquely enriched in EGFR_double, which exhibits a distinct lipid-glycosylation metabolic profile that stabilizes CD44 expression. Cell-cell communication analysis revealed enhanced COL4A3-CD44 interactions between EMT-like malignant MP4 cells and metabolically reprogrammed, immunosuppressive alveolar macrophages in EGFR_double compared with Non_EGFR. MIHC confirmed in situ proximity of this significantly increased COL4A3-CD44 co-localization in EGFR_double. Furthermore, drug sensitivity analysis identified specific vulnerabilities of this subtype. Our study identifies a previously unrecognized malignant-myeloid niche and TME in EGFR_double. These findings provide a translational framework for identifying a potential novel therapeutic targets and suggest that combinatorial strategies targeting the COL4A3-CD44 interaction may overcome therapeutic recalcitrance in this challenging clinical population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.